地舒单抗与阿仑膦酸钠治疗骨质疏松症的效果比较

Comparison on Effects of Denosumab versus Alendronate Sodium in Treatment of Osteoporosis

目的:分析地舒单抗与阿仑膦酸钠治疗骨质疏松症的效果。方法:选取2020年8月—2021年8月北京市朝阳区东风社区卫生服务中心收治的81例骨质疏松症患者作为研究对象,依据随机数字表法分为阿仑磷酸钠组(n=40)与地舒单抗组(n=41)。阿仑磷酸钠组采用阿仑磷酸钠联合碳酸钙D_(3)、维生素D_(2)治疗,地舒单抗组采用地舒单抗联合碳酸钙D_(3)、维生素D_(2)治疗。比较两组治疗效果。结果:地舒单抗组治疗总有效率高于阿仑磷酸钠组,差异有统计学意义(P=0.030)。治疗后,两组L_(2)、L_(3)、L_(4)、股骨颈处骨密度高于治疗前,且地舒单抗组高于阿仑磷酸钠组,差异有统计学意义(P<0.05)。治疗6个月、1年,两组疼痛评分低于治疗前,且治疗1年低于治疗6个月,地舒单抗组低于阿仑磷酸钠组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:相较于阿仑磷酸钠,地舒单抗治疗骨质疏松症的效果更佳,可增加患者骨密度,减轻疼痛,且安全性较高。

Objective:To analyze the effects of denosumab and alendronate sodium in treatment of osteoporosis.Methods:A total of 81 patients with osteoporosis admitted to Dongfeng Community Health Service Center in Chaoyang District of Beijing from Au⁃gust 2020 to August 2021 were selected as the study subjects.They were divided into alendronate sodium group(n=40)and deno⁃sumab group(n=41)according to the random number table method.The alendronate sodium group was treated with alendronate so⁃dium and calcium carbonate D_(3)、vitamin D_(2),while the denosumab group was treated with denosumab and calcium carbonate D3、vitamin D_(2).The treatment effects of the two groups were compared.Results:The total effective rate of treatment in the denosumab group was higher than that in the alendronate sodium group,and the difference was statistically significant(P=0.030).After treat⁃ment,the bone mineral density of L_(2),L_(3),L_(4) and femoral neck in the two groups was higher than that before treatment,and this in⁃dex in the denosumab group was higher than that in the alendronate sodium group,and the difference was statistically significant(P<0.05).After 6 months and 1 year of treatment,the pain scores in the two groups were lower than those before treatment,the pain scores in the two groups after 1 year of treatment were lower than those after 6 months of treatment,the pain scores in the de⁃nosumab group were lower than those in the alendronate sodium group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Com⁃pared with alendronate sodium,denosumab has a better effect in the treatment of osteoporosis,and can increase bone mineral den⁃sity and relieve pain,with a high safety.